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Abstract
Background: Aseptic loosening is a significant impediment to joint implant longevity. Prosthetic wear particles are
postulated to play a central role in the onset and progression of periprosthetic osteolysis, leading to aseptic loosening
of the prosthesis.
Methods: We investigated the inhibitory effects of a lentivirus-mediated short hairpin RNA that targets the TNF-alpha
gene on the particle-induced inflammatory and osteolytic changes via macrophages both in vitro and in vivo. An siRNA
sequence targeting the mouse TNF-alpha gene from four candidates, transcribed in vitro, was screened and identified. A
lentivirus vector expressing short hairpin RNA (shRNA) was then constructed in order to facilitate efficient expression of
TNF-alpha-siRNA. Lentivirus-mediated shRNA was transduced into cells of the mouse macrophage line RAW 264.7.
Ceramic and titanium particles were introduced 24 h after lentivirus transduction to stimulate cells. TNF-alpha expression,
represented by both mRNA and protein levels, was quantified with real-time PCR and ELISA at all time intervals.
Lentivirus-mediated shRNA suspension was locally administered into the murine calvarial model, followed by local
injection of particles. A multi-slice spiral CT scan was used to evaluate the osteolysis of the calvaria by detecting the
width of the cranial sutures.
Results: Macrophages developed pseudopods when co-cultured with particles. Lentivirus-mediated shRNA was shown
to effectively inhibit the expression of TNF-alpha at both the mRNA and protein levels in RAW 264.7. The multi-slice spiral
CT scan showed that the lentivirus-mediated shRNA significantly suppressed osteolysis of mouse calvaria.
Conclusions: Our investigation highlighted the results that lentivirus-mediated shRNA targeting the TNF-alpha gene
successfully inhibited particle-induced inflammatory and osteolytic changes both in vitro and in vivo. Therefore, lentivirus-
mediated gene therapy may provide a novel therapeutic approach to aseptic joint loosening.
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Background
Total joint replacement is a common procedure and has
been proven to be highly successful for the treatment of
advanced arthropathy. Internationally, nearly 1.5 million
total arthroplasties are performed every year [1]. Although
considerable efforts have been made to improve the effi-
cacy and quality of total joint replacement, there are still
numerous challenges facing the long-term success of
arthroplastic surgery. Aseptic prosthetic loosening consti-
tutes one of the most common causes of arthroplasty
failure [1]. Additionally, there are, as yet, no approved
conservative management methods to prevent or inhibit
periprosthetic osteolysis. With increasing life expectancy
and arthroplasties becoming more common in younger
and more active patients, osteolytic aseptic loosening has
risen to become the principle cause for revision surgery.
Understanding the exact mechanism of aseptic loosening
and developing solutions to contain the loosening process
are thus a critical and urgent task. Recent attempts have
been directed at understanding and changing osteolysis
through intervention at the molecular level.
Wearing a prosthesis is believed to play a leading role in
the onset and progression of periprosthetic osteolysis. The
particles resulting from internal wear induce osteolysis, as
has been evidenced by in vitro studies, as well as in vari-
ous animal models [2]. Titanium-alloy components have
been broadly used in total joint replacement [3]. Particu-
late titanium debris is one of the most frequently seen
metal debris types in tissues at a failed joint prosthesis. As
an emergent material, ceramic has also been widely used
in total joint replacement [4].
Aseptic loosening is believed to be initiated by the inter-
actions between periprosthetic cells and wear particles. It
has also been highlighted that macrophages make up 60–
80 % of the entire cellular population around loosening
periprosthetic tissues [5]. Inflammatory cytokines contrib-
ute to the progression of wear particle-induced inflamma-
tory osteolysis, including TNF-α, IL-1β, IL-6, and IL-10 [6].
These inflammatory cytokines further become direct or in-
direct stimulants to osteoclast attachment, differentiation,
activation, and maturation, resulting in bone resorption
around implants and possible implant failure [7]. TNF-
alpha has been shown to play an important role in osteo-
clastogenesis and osteolysis [8]. This is supported by the
fact that etanercept, a soluble inhibitor of TNF-a, reduces
wear debris particle-induced bone resorption and osteoclast
formation to a background level in both normal mice and
those transferred with human TNF-alpha (hTNF-alpha), a
phenomenon which was also observed in a bone wafer pit
assay [9]. These studies all strongly suggest that this could
be a promising way to inhibit osteoclastogenesis and oste-
olysis induced by wear debris particles by limiting the TNF-
alpha-releasing macrophages. Antagonist, antibody, and
bisphosphonate therapies have the disadvantages of high
dose and frequency of administration. In particular, several
studies have shown that the nitrogen-containing bispho-
sphonates, such as alendronate and zoledronate, have been
shown to inhibit the osteolysis resulting from wear debris,
as well as to increase bone mineral density around implants
[10], but their side-effects, such as fever and throat and
stomach ulcers, as well as their low bioavailability, consti-
tute challenges for systemic treatment [11]. These limita-
tions have increased the demand for a better TNF-alpha
inhibitor with improved potency, sustainability, and safety.
As a post-transcriptional gene silencing mechanism,
RNA interference (RNAi) has demonstrated great promise
for the study of human gene function, signal transduction
research, and gene therapy [12]. Recently, RNAi–based ap-
proaches involving small interfering RNA (siRNA) and
short hairpin RNA (shRNA) have been widely utilized to si-
lence the expression of many target genes. However, there
are major barriers to the possible therapeutic use of RNAi.
The most apparent challenges for the use of siRNA are in-
efficient transfection in primary cells and the transient
knockdown effect. In contrast, shRNA provides a more sus-
tained inhibitory effect than chemically synthesized siRNA.
Nevertheless, some disadvantages remain, including the
lack of sustained shRNA expression and an effective and
nontoxic in vivo delivery system. To overcome these limita-
tions, several attempts have been made to this end, such as
the selection of conserved viral sequences to be RNAi tar-
gets and the development of viral delivery systems that ex-
press siRNA or shRNA [13]. Among these delivery systems,
the lentivirus is an attractive option, because it is a well-
established vehicle for in vivo gene transfer and is capable
of stably transducing cells in both dividing and quiescent
phases [14]. In addition to its ability to stably integrate into
the host’s genome, the remarkable packaging capacity of
lentiviral vectors also renders them to be effective gene
transfer tools [15]. Additionally, lentiviral vectors show
minimal immunogenicity [16]. Lentivirus vectors encoding
anti-sense targeting sequences have been shown to be free
from obvious side effects in clinical trials [17]. Therefore,
the lentiviral vector is a suitable delivery method for RNAi
technology in order to facilitate the development of thera-
peutic strategies.
In the present study, we aimed to find an efficient
system by fabricating a recombined lentivirus vector en-
coding shRNA targeted against TNF-alpha and examining
the TNF-alpha knockdown efficiency in mouse macro-
phages, as well as the in vivo effect on reducing the oste-




Commercially pure titanium particles of 4.507 g/cm3
were purchased from Alfa Aesar (Ward Hill, MA, USA),
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and alumina ceramic particles of 3.53 g/cm3 from Ceram
Tec (Plochingen, Germany). All particles were dissemi-
nated in pure water and filtered through Millipore filter
membranes (Billerica, MA, USA) of different diameters
(0.2 μm and 1.2 μm) to select particles with a target size
between 0.2 μm and 1.2 μm. An image analysis system
(NIKON, Japan) was used to measure the exact size of
the particles, and the results were 0.82 ± 0.12 μm and
0.84 ± 0.14 μm for the filtrated titanium and ceramic
particles, respectively. All particles were rinsed with
70 % ethanol for 24 h at room temperature and then
dried in an oven before being sterilized with ethylene
oxide. Based on particle weight and density, particles in-
cubated in phosphate buffered saline (PBS) were ad-
justed to 4 × 108 μm3/ml in concentration. The level of
endotoxin in particle solutions was detected using the
Limulus Amebocyte Lysate Assay (QCL-1000; Bio Whit-
taker, Walkersville, Maryland, USA), and the result was
below the detection level of 0.01 EU/ml.
Construction of lentiviral vector expressing TNF-alpha-
specific shRNA
Four siRNA sequences against the mouse TNF-alpha gene
(Gene Bank Accession No NM_004517.2) were designed
using online siRNA software. Preliminary experiments indi-
cated that the best performing TNF-alpha siRNA sequence
with the highest inhibitory efficiency was 5’-GCAAACA-
GAGCATGGTCAA-3’. Meanwhile, a missense siRNA (MS
siRNA): 5’-TAATCGTCGT AGACGGTTG-3’ was used as
the control. Based on the siRNA sequences described
above, an shRNA cassette was designed with 19 nucleotides
(nt) of the target sequence, a loop sequence (TTCAA-
GAGA), the reverse complement of the 19-nt target se-
quence, and then a stop codon for the U6 promoter, as well
as digestion sites for HpaI and XhoI. Following the design
described above, the shRNA cassettes were synthesized
along with their complementary strands. The shRNAs were
inserted into the pFU-GW-iRNA lentivirus vector, which
contained a CMV-driven EGFP reporter gene and a U6
promoter upstream from the restriction sites (HpaI and
XhoI). All of the constructs were ascertained by sequence
analysis. The vector was designed to co-express green fluor-
escent protein (GFP) cloned from a copepod. Bearing the
shRNA sequences and pPACK Packaging Plasmid Mix
(System Biosciences), the pFU-GW-iRNA lentivirus vector
was co-transfected into 293TN cells with Lipofectamine
2000 (Invitrogen). After 48 h, viral supernatants were
harvested and passed through 0.45 μm filters. The target
lentivirus and the negative control lentivirus expressing
TNF-alpha-siRNA and non-targeting sequence were de-
noted as TNF-alpha-RNAi-LV and NC-GFP-LV, respect-
ively. Expression levels of GFP were studied by FACS
analysis and PCR. In order to calculate the virus titers, the
number of cells was multiplied by both the percentage of
GFP-positive cells and the dilution factor, resulting in the
formation of the titer units (TU)/ml. The concentration
was 5 × 108 TU (titer unit)/ml.
Cell culture and lentivirus transduction
RAW264.7, the murine macrophage cell line, was
obtained from American Type Culture Collection
(ATCC Number: TIB-71). The cells were seeded and
cultured in 96-well tissue culture plates (Costar, Cam-
bridge, MA, USA) in DMEM medium with 10 % fetal
bovine serum (FBS) (Hyclone). Cells were incubated
overnight in a humidified incubator at 37 °C with
5 % CO2 to improve the adherence of cells to the
plates. Trypan blue dye exclusion was used for cell
quantitation and the viability assays, with viability
exceeding 98 % for all trials.
For lentivirus transduction, RAW 264.7 macro-
phages were infected with either TNF-alpha-RNAi-LV
or NC-GFP-LV in serum-free growth medium with
5 mg/ml polybrene at multiplicities of infection
(MOI) of 150, which was optimized from the toxicity
curve before transduction. After 8 h’ of culturing, the
medium was substituted by fresh DMEM complete
medium, in order to remove debris and inactive lenti-
viruses before the cells were continuously incubated
for another 72 h. Three days after transfection, the
transfection efficiency was examined by fluorescent
microscopy.
Particle stimulation and molecular analysis of cytokines
expression
After lentivirus transduction, cells seeded in 6-well
plates were digested. The particles were added to all of
the experimental groups, except for the control group.
They were then developed into suspensions at a final
concentration of 100:1 (particle volume μm3: cell num-
ber) and supplemented to cultures, whereupon the cul-
ture plates were gently agitated for 10 min. Experimental
grouping was made up of seven groups, as follows:
Control Group: free of any interference measure or
particle stimulation
TI Group: free of any interference measure, but
stimulated with titanium particles
TI + TNF-LV Group: transfected with TNF-alpha-
RNAi-LV and stimulated with titanium particles
TI + N.C-LV Group: transfected with NC-GFP-LV and
stimulated with titanium particles
CE Group: free of any interference measure, but
stimulated with ceramic particles
CE + TNF-LV Group: transfected with TNF-alpha-
RNAi-LV and stimulated with ceramic particles
CE + N.C-LV Group: transfected with NC-GFP-LV and
stimulated with ceramic particles
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Experiments were performed three times in each group.
After particle stimulation, the mRNA and supernatant
were collected (0.5 h, 3 h, and 6 h for mRNA, and 6 h,
12 h, 24 h, and 48 h for supernatant), in order to deter-
mine interference efficiency by real-time PCR and ELISA.
An RNA-to-cDNA reverse transcription was performed
with Primescript RT reagent (TaKaRa, Kyoto, Japan). The
mRNA levels were determined using real-time PCR on the
Roche Light Cycler 480 System (Roche, Mannheim,
Germany). With Primer 5.0, the following gene-specific
primers were designed (5’ to 3’): GAPDH, TGTGTCC
GTCGTGGATCTGA (forward) and TTGCTGTTGA
AGTCGCAGGAG (reverse), as well as TNF-alpha, AG
CCCCCAGTCTGTATCCTT (forward) and CTCCCTT
TGCAGAACTCAGG (reverse). The product was detected
with the SYBR green dye, SYBR Premix Ex Taq (TaKaRa,
Kyoto, Japan). The results of GAPDH amplification
efficiency and TNF-alpha primers were 1.976 and 2.022,
respectively. The comparative CT (threshold cycle)
method with arithmetic formulas was used to determine
the relative level of gene expression for both the target
and house-keeping genes. Since the negative controls are
referred to as the calibration factor, all of the other quan-
tities are expressed as an n fold difference relative to the
negative control.
The protein production of TNF-alpha in the superna-
tants was assayed with an immunoassay ELISA kit (Invi-
trogen, Carlsbad, CA, USA) as per the manufacturer’s
instructions.
Murine calvarial model
Male C57BL/6 mice, aged 12 weeks, were purchased from
the Center of Animal Experiments of Sun Yat-sen Univer-
sity (Guangzhou, China). All animal handling and experi-
ment procedures were performed in compliance with the
guidelines of the National Institutes of Health for animal
care, and all animal experiments were approved by The
Memorial Hospital of Sun Yat-Sen University.
In this study, 49 mice were randomized into seven
groups, with seven mice in each group:
Control: PBS was administered locally into the cranial
sutures without lentivirus infection or particle
stimulation
TI: stimulated with titanium particles, free from
interference measures
TI + TNF-LV: stimulated with titanium particles and
transfected with TNF-alpha-RNAi-LV.
TI + N.C-LV: stimulated with titanium particles and
transfected with NC-GFP-LV
CE: stimulated with ceramic particles, free from
interference measures
CE + TNF-LV: stimulated with ceramic particles and
transfected with TNF-alpha-RNAi-LV
CE +N.C-LV: stimulated with ceramic particles and
transfected with N.C control-lentivirus mediated shRNA
Locally injecting wear particles in mice can establish a
model of particle-induced osteolysis [18]. A 1*1 cm me-
dian incision was made on the surface of murine calvaria.
Periosteum stripping was performed to fully expose the
cranial sutures. A piece of 0.7*0.7 cm medical gelfoam was
placed in order to medially cling to the surface of the cal-
varia. A 500 μl particle suspension (4 × 108 μm3/ml) was
slowly injected into the intervals between the cranial su-
tures and the gelfoam to provoke an osteolytic response.
The skin was then sutured. After 24 h, 0.5 ml of culture
medium containing 2 × 107 TU of TNF-alpha-RNAi-LV,
NC-GFP-LV, or PBS alone was slowly injected into the in-
tervals between the cranial sutures and the gelfoam, using
a 1 ml injector. Since preliminary experiments have shown
that particles injected locally on the surface of murine cal-
varia induced significant osteolysis by the 14th day, the
mice in our study were sacrificed with carbon dioxide as-
phyxiation for CT scan analysis 14 days after transfection.
All experiments involving the construction and in vivo
evaluation of the lentiviral vectors were completed under
bio-safety level II containment.
CT scan analysis
The osteolysis of the calvaria was evaluated based on the
width of the cranial sutures after 2 weeks using multi-
slice spiral CT scans (Fig. 1). The cranial CT scans were
performed on a 64-slice spiral CT (Sensation 64,
Siemens Medical Systems, Germany). The parameters of
each scan were set at an axial collimation of 12 ×
0.6 mm, a pitch of 0.8, a tubular voltage of 80 KV, and a
tubular current of 120 mAs. The raw data obtained were
reconstructed into contiguous 0.6-mm thick slices at
0.3 mm increments, with a field of view of 30 mm ×
30 mm and a matrix of 512 × 512, using a B40 soft tis-
sue, as well as a U75 bone algorithm. These two sets of
thin-slice images were respectively post-processed by
volume rendering (VR) and multi-planar reformation
(MPR) to evaluate the osteolysis of calvaria and to per-
form related measurements. The detailed morphology of
cranial sutures was observed by three-dimensionally dis-
played cranial sutures on a VR image, using appropriate
threshold values. The MPR planes were first adjusted to
achieve orthogonal three-dimensional cranial MPR
images. Then the largest cranial suture width was
measured on the obtained orthogonal coronal images.
Statistical analysis
Results are shown as mean ± SD. ANOVA was performed
to analyze differences between groups. Significance was set
at a p value of < 0.05. All statistical analyses were performed
using SPSS (version 16.0; SPSS, Chicago, IL, USA).
Qin et al. BMC Musculoskeletal Disorders  (2016) 17:431 Page 4 of 10
Results
Macrophages co-cultured with wear particles
A scanning electron microscope (SM-6330 F-Field
Emission, JEOL, Japan) was used to observe the macro-
phages after particle stimulation, which showed that the
macrophages in a stimulation-free environment basically
maintained smooth and non-distorted contours (Fig. 2a).
When co-cultured with particles, however, macrophages
developed pseudopods (Fig. 2b).
Transfection efficiency of lentivirus-mediated shRNA in
RAW264.7macrophages
The efficiency of lentivirus-mediated shRNA transfection
into RAW264.7 macrophages was determined by GFP
fluorescence. The numbers of cells and fluorescent spots in
the same visual field were counted with light and fluores-
cence microscopes, respectively. The transfection efficiency
of lentivirus-mediated shRNA via cationic liposomes was
85.2 ± 3.5 % (Fig. 3).
Significant down-regulation of TNF-alpha mRNA in
RAW264.7 macrophages by lentivirus-mediated shRNA
The results of multiple comparisons among different time
points demonstrated that the TNF-alpha mRNA was sig-
nificantly reduced at 0.5 h, 3 h, and 6 h after transfection,
having reached peak reduction at the 3 h time point
(Fig. 4a, b). The down-regulation of TNF-alpha mRNA in
the Particle + TNF-LV group was significant when com-
pared with the Particle and Particle + N.C-LV groups (p <
0.05) at any time point, and was insignificant between the
Fig. 1 Measurement of cranial suture on orthogonal MPR images. The thin-slice images were reformatted with the MPR technique. The orthogonal
sagittal (a), axial (b), and coronal planes (c) of the murine head were obtained. On the orthogonal coronal image (d), the largest cranial suture width
(between the two arrows) was determined and measured
Fig. 2 Macrophage and particles under scanning electron microscopy. a Non-stimulated macrophage alone (8000×), b Macrophages stimulated
with titanium particles (0.82 ± 0.12 μm) (5500×)
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Particle and Particle + N.C-LV groups (p > 0.05) (Fig. 4a,
b). The inhibition ratios [(mRNA levels of the Particle
group minus those of the Particle + TNF-LV group)/Par-
ticle group] are available in Table 1. Results also revealed
that TNF-alpha expression in TNF-LV-transfected macro-
phages was suppressed by 53.22 and 46.52 % for titanium
and ceramic particles, respectively, 3 h after the introduc-
tion of particles.
Significant down-regulation of TNF-alpha protein in
RAW264.7 macrophages by lentivirus-mediated shRNA
ELISA analysis of the cell supernatants demonstrated
TNF-alpha gene silencing (Fig. 5a, b). As shown, TNF-
alpha levels increased remarkably in the Particle group
compared with the control, 6 h after stimulation began,
and reached the peak after 24 h. We assayed protein levels
among the experiment groups at the 4 time points for the
RNAi inhibitory effects. The down-regulation of TNF-
alpha protein in the Particle + TNF-LV group was signifi-
cantly lower compared with the Particle and Particle +
N.C-LV groups (p < 0.05), and was insignificant between
the Particle and Particle + N.C-LV groups (p > 0.05)
(Fig. 5a, b). The inhibition ratios for the Particle + TNF-
LV group are displayed in Table 1. In addition, TNF-alpha
protein levels in TNF-LV-transfected macrophages were
suppressed by 37.18 and 42.37 % with titanium and
ceramic particles, respectively. Finally, when the TI +
TNF-LV and CE + TNF-LV groups were compared at the
same protein levels for RNAi inhibitory effects, the results
concluded no significant difference in RNA interference
effects (p > 0.05).
Inhibited particle-induced osteolysis in vivo, due to
lentivirus-mediated TNF-alpha shRNA
The width of the cranial suture at the widest point was
measured in order to assess the particle-induced osteoly-
sis in the murine calvarial model. Significant narrowing
of cranial suture width was revealed in the Particle +
TNF-LV group compared with the Particle and Particle
+ N.C-LV groups (p < 0.01) (Fig. 6), suggesting that
lentivirus-mediated shRNA interference reduced the
osteolysis by approximately 40 % in the Particle + TNF-
LV group. The width difference was negligible between
the Particle and Particle + N.C-LV groups (p > 0.05).
Discussion
Inflammation and the consequent osteolysis due to the
presence of wear particles are both believed to be involved
in the pathogenesis of aseptic loosening [19], which is, un-
fortunately, amenable by no other means than surgical re-
vision. Efforts to prevent osteolysis have focused on
improvements in implant design, biomaterials, or surgical
Fig. 3 Transfection efficiency of lentivirus-mediated shRNA interference determined by fluorescence microscopy analysis. a and c transfected macrophage
cells under light microscopy of shRNA-LV and NC-LV group (20×); b and d transfected macrophage cells under fluorescence microscopy of the same visual
field of shRNA-LV and NC-LV group (20×)
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techniques [20]. These approaches are insufficient, how-
ever, in regards to eliminating aseptic loosening, due to
their inability to completely block particle generation from
the bearing surfaces. Recently, a new approach was identi-
fied, starting with understanding and alleviating inflamma-
tory osteolysis through pharmacological intervention [21].
Nevertheless, the delivery of an adequate level of cell spe-
cific therapy to the site of periprosthetic inflammation
without causing systemic side effects is a formidable
challenge. Researchers have been motivated by the current
unsatisfactory methods for prevention and treatment of
aseptic loosening to experiment and gain further insights
from progress that has already been made in the study of
the mechanisms of inflammation. Most previous studies
have focused on methods for reducing inflammation
caused by wear particles, while a few have investigated
whether down-regulated inflammation could inhibit
osteolysis.
Macrophages play a pivotal role in these processes [22].
Macrophages phagocytose implant-derived wear particles,
leading to cytokine secretion, foreign-body-associated
granulomatous and inflammatory reactions, osteoclastogen-
esis, activation, and subsequent osteoclastic bone resorption
[23]. In the presence of wear debris particles, macrophages
produce many cytokines, some of which stimulate the dif-
ferentiation of osteoclast precursors, while others activate
the mature osteoclasts [24]. The pro-inflammatory TNF-
alpha is the dominant cytokine found around prostheses,
and is known as a potent generator of bone resorption re-
lated to aseptic loosening [25]. It fuels osteoclast
Fig. 4 Multiple comparison tests of TNF-alpha mRNA levels at different
time points. mRNA levels of TNF-alpha in transfected macrophage cells
at 3 h after particle stimulation. *p< 0.05 When compared to the control
group; *p< 0.05 when compared to the Particle + TNF-LV group. a Titan-
ium particles treatment; b Ceramic particles treatment
Table 1 Inhibition ratios of mRNA levels and protein levels
Particles mRNA levels mean ± SD protein levels mean ± SD (pg/ml)
Particle Particle + TNF-LV Particle + N.C-LV IRa Particle Particle + TNF-LV Particle + N.C-LV IRa
TI 24.06 ± 5.06 11.26 ± 3.48 1.50 ± 0.57 53.22 % 780.12 ± 36.36 490.03 ± 8.80 730.06 ± 45.88 37.18 %
CE 9.01 ± 1.49 4.82 ± 0.22 1.50 ± 0.57 46.52 % 572.11 ± 38.41 329.73 ± 17.22 527.11 ± 44.68 42.37 %
aIR (Inhibition ratio) = (mRNA or protein levels of Group Particle minus Group Particle + TNF-LV)/Group Particle. There were no significant differences in RNAi
inhibitory effects among titanium and ceramic particle stimulation groups in both mRNA levels and protein levels (P > 0.05)
Fig. 5 Multiple comparison tests of TNF-alpha protein levels for different
time points. Protein levels of TNF-alpha in transfected macrophage cells
at 24 h after particle stimulation. *p< 0.05 When compared to the
control group; *p< 0.05 when compared to the Particle + TNF-LV group.
a Titanium particles treatment; b Ceramic particles treatment
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differentiation by up-regulating receptor activator nuclear
factor κB ligand (RANKL) in stromal cells, as well as the
macrophage colony stimulating factor (M-CSF) of macro-
phages, and enhancing the sensitivity of osteoclast precur-
sors to RANKL [26]. In addition, TNF-alpha has been
demonstrated to act directly on certain genes and their
products, a feature crucial for osteoclast formation, differ-
entiation, and activation [27]. The feasibility of inhibiting
inflammation by blocking TNF-alpha has been evidenced
in several therapies. For example, anti-TNF therapeutics
have already been proven to be effective in fighting
rheumatoid arthritis, a chronic inflammatory bone disease
characterized by bone damage and elevated osteoclastic
bone resorption around the affected joints [28]. There are,
however, significant disadvantages to such therapy [29].
RNAi is a useful target for the analysis of gene function
and a candidate for potential therapeutic strategies in vari-
ous conditions [30]. The delivery of SiRNA into cells repre-
sents the bottleneck for RNAi therapy. Two mechanisms
prevail in RNAi, namely the direct delivery of chemically
synthesized siRNA into cells or the continuous production
of siRNAs within cells via transcription. Chemically synthe-
sized siRNA can be introduced into cells via conventional
means, such as liposomes, polyethylenimine, or electropor-
ation. However, the short-lived knockdown effect of these
techniques put them at a disadvantage. More recently,
therefore, the attention of many researchers has been
drawn to expression vectors that enable mammalian cells
to synthesize their own siRNA. A number of viral systems
are being developed for ex vivo and in vivo gene transfer,
among which are retroviruses, adenoviruses, herpes-
simplex viruses, and adeno-associated viruses [31]. In the
present study, a lentivirus vector was selected as the shRNA
delivery vehicle due to its ability to infect both dividing and
non-dividing cells with high efficiency, and to produce sus-
tained gene expression by integrating into the host genome
[32]. This methodology makes it possible for cells to con-
tinuously synthesize siRNA, an important step for the long-
term silencing of a target gene [33]. The current study has
proven the feasibility and efficacy of LV-mediated siRNA in
hindering particle-induced inflammation. LV-shRNA was
successfully constructed and proven safe for macrophages,
and the LV-mediated TNF-alpha siRNA was shown to in-
hibit TNF-alpha expression with high efficiency, at both
mRNA and protein levels. Furthermore, LV-shRNA
brought about a significant hypoexpression of TNF-alpha,
thereby alleviating osteolysis in murine calvaria. Our study
justifies the use of lentivirus in aseptic loosening gene ther-
apy studies. As indicated by subsequent experiments, this
lentiviral transgenic system can be effectively transfected
into RAW264.7 macrophages, with 85 % gene transfection
efficiency at an MOI of 150. In addition, it significantly and
specifically down-regulated TNF-alpha at both the mRNA
and protein levels.
In addition to the dose, size, and shape of the particle,
its material property is considered to be a major param-
eter influencing the consequent immune response [34].
With this background, the intervention discussed in this
study was caused by two different wear particles, titan-
ium and ceramic, which represent the most relevant and
frequently observed biological sources of wear debris ob-
served in clinical practice.
Under in vivo conditions, particles disperse randomly as
they interact with the local tissue. The animal model used
in our research was first described by Merkel, et al. [35].
Studies on small animals are cost-effective, quick, sensitive,
and efficacious in screening agents with the potential to
prevent the bone loss associated with wear particles. The
murine calvarial osteolysis model serves as a simulation of
the mechanisms responsible for the aseptic loosening ob-
served in human joints. With desirable sensitivity and cost-
effectiveness, its use in this study helps provide insight into
the responses of inflammatory osteolysis induced by parti-
cles during aseptic loosening. However, there are docu-
mented limitations to the murine model [36]. In particular,
the process of osteolysis in the murine calvarial model is
by no means identical to that seen in human patients.
Thus, the results of the study described here must be inter-
preted with caution, and future studies involving large ani-
mals and humans are necessary to confirm the efficacy of
the agents tested in this model. Although the model estab-
lished in our study only represented an acute setting, it
nevertheless served as an efficient, sensitive, and cost-
effective way to study the cellular and molecular responses
of particle-induced inflammation. In other words, this
model enabled us to efficiently demonstrate the expected
results. As the optimal clinical protocol for wear particle
induced inflammation has not yet been established, and
Fig. 6 The width of the murine cranial suture was measured on the
obtained orthogonal coronal images by 64-slice spiral CT. Significant
reduction of cranial suture width was revealed in the Particle + TNF-
LV group compared with the Particle and Particle + N.C-LV groups
(P < 0.01). There was no difference between the Particle and Particle
+ N.C-LV groups in this parameter (P > 0.05)
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any adverse effects of lentivirus treatment are yet to be
thoroughly understood, further studies are warranted. In
our murine cranial model, the particles were directly im-
planted in the periosteal space, instead of wearing off from
a real prosthesis, as encountered in the ‘replace the joint
with an implant’ scenario [37]. Due to the ready-to-use
wear particles, the osteolysis was quickly evident. As for
the delivery method, intravenous injection is the most
widely used route to introduce lentivirus-mediated shRNA
in vivo, because of its convenience and efficacy. However,
the majority of lentivirus-mediated shRNA is not taken up
by target tissues, making side effects inevitable due to the
systemic down-regulation of the target gene. Recently, vari-
ous methods of local siRNA administration have been
suggested, which have been shown to result in higher silen-
cing efficacy and fewer systemic side effects [38, 39]. The
results from our study are consistent with this trend. All of
these studies indicate that the local administration of
lentivirus-mediated shRNA might be a promising strategy
in the field of RNAi research. Studies in which lentiviral
vectors are delivered directly to the murine calvaria are not
yet available. In the present study, however, we came closer
by introducing lentivirus-mediated shRNA via local injec-
tion, a modification made to the conventional administra-
tion method in the murine calvarial model.
By taking advantage of the strengths of murine calvaria, a
lentiviral vector, and local administration, we explored the
role of a novel gene therapy in inhibiting particle-induced
inflammation and osteolysis. As shown by the experiments,
a single dose of LV-mediated siRNA targeting TNF-alpha
resulted in the hypoexpression of the corresponding mRNA
by up to 80 %, and markedly compromised inflammatory
responses in murine calvaria for at least 2 weeks. In
addition, the fact that GFP fluorescence was found to be
localized in the pouch area suggested that local administra-
tion was a safe and effective delivery route for the siRNA.
Combined, these results lead to the conclusion that LV-
mediated TNF-alpha shRNA remarkably inhibit particle-
induced inflammation and osteolysis in the murine calvarial
model. This finding serves as a building block for in vivo
RNAi therapy in addressing aseptic loosening.
Conclusions
In summary, our investigation shows that lentivirus-
mediated shRNA targeting the TNF-alpha gene inhibits
particle-induced inflammation and osteolysis both in vitro
and in vivo. Conscious efforts have been made in this
study to investigate an alternative therapeutic strategy for
applying RNAi for the amelioration of this condition. Al-
though the gap between this trial and clinical care for
aseptic loosening has not yet been filled, this study has
yielded insight into the potential therapeutic role of siRNA
in this disease. In order to assess the osteolytic mediators
in particle-induced aseptic loosening, the quantitative
assessment of inflammatory cytokines on the murine
calvarial surface is worthy of research.
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